<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03504982</url>
  </required_header>
  <id_info>
    <org_study_id>18979</org_study_id>
    <secondary_id>2017-003094-33</secondary_id>
    <nct_id>NCT03504982</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat</brief_title>
  <official_title>Study to Clinically Evaluate the QT/QTc Interval Prolongation Potential of Vericiguat in Patients With Stable Coronary Artery Disease in a 2-arm, Placebo-controlled, Randomized, Double-blind, Double-dummy Design Including a Vericiguat Multiple-dose Part With Fixed up Titration Periods and Moxifloxacin as Positive Control (for Assay Sensitivity Testing, Nested Into the Placebo Treatment)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to investigate whether there is a clinically
      meaningful effect on QTc change from baseline relative to placebo after administration of 10
      mg at steady state in patients with stable CAD (coronary artery disease).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Actual">February 26, 2019</completion_date>
  <primary_completion_date type="Actual">November 29, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-matched placebo-corrected change from baseline of the QT interval corrected according to Fridericia (QTcF) after 10 mg vericiguat at steady state.</measure>
    <time_frame>Baseline, day 56 (steady state 10 mg) of vericiguat treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-matched placebo-corrected change from baseline of QTcF after 1st dose of 2.5 mg vericiguat</measure>
    <time_frame>Baseline and day 1 of vericiguat treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-matched placebo-corrected change from baseline of QTcF after 1st dose of 5 mg vericiguat</measure>
    <time_frame>Baseline and day 15 (+/- 3 days) of vericiguat treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-matched placebo-corrected change from baseline of QTcF after 1st dose of 10 mg vericiguat</measure>
    <time_frame>Baseline and day 29 (+/- 3 days) of vericiguat treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-matched placebo-corrected change from baseline of QTcF after 2.5 mg vericiguat at steady state</measure>
    <time_frame>Baseline and day 14 (+/- 3 days) of vericiguat treatment (steady state 2.5 mg)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-matched placebo-corrected change from baseline of QTcF after 5 mg vericiguat at steady state</measure>
    <time_frame>Baseline and day 28 (+/- 3 days) of vericiguat treatment (steady state 5 mg)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-matched placebo-corrected change from baseline of QTcF after single dose of moxifloxacin</measure>
    <time_frame>Baseline and day 8 of the moxifloxacin treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of vericiguat in plasma after first dose (Cmax)</measure>
    <time_frame>On profile day 1; Timeframe: 0 - 5 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration of vericiguat in plasma after first dose (tmax)</measure>
    <time_frame>On profile day 1; Timeframe: 0 - 5 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of vericiguat in plasma after multiple doses (Cmax, md)</measure>
    <time_frame>On profile days: 8, 14, 15, 28, 29, 42, 43, 50 and 56; Timeframe: 0 - 5 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration of vericiguat in plasma after multiple doses (tmax, md)</measure>
    <time_frame>On profile days: 1, 8, 14, 15, 28, 29, 42, 43, 50 and 56; Timeframe: 0 - 5 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of moxifloxacin in plasma after single dose (Cmax)</measure>
    <time_frame>On moxifloxacin profile days (day 8 and 50); Timeframe: 0 - 5 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration of moxifloxacin in plasma after single dose (tmax)</measure>
    <time_frame>On moxifloxacin profile days (day 8 and 50); Timeframe: 0 - 5 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment sequences: A*-B-C-D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment sequences: D-A-B-C*</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vericiguat (BAY1021189)</intervention_name>
    <description>A : 2.5 mg vericiguat A*: 2.5 mg vericiguat B : 5 mg vericiguat C : 10 mg vericiguat C*: 10 mg vericiguat</description>
    <arm_group_label>Treatment 1</arm_group_label>
    <arm_group_label>Treatment 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>D: 400 mg moxifloxacin</description>
    <arm_group_label>Treatment 1</arm_group_label>
    <arm_group_label>Treatment 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A : vericiguat placebo 10 mg A*: vericiguat placebo 10 mg + moxifloxacin placebo B : vericiguat placebo 10 mg C : vericiguat placebo 2.5 mg C*: vericiguat placebo 2.5 mg + moxifloxacin placebo D : vericiguat placebo 2.5 mg + vericiguat placebo 10 mg</description>
    <arm_group_label>Treatment 1</arm_group_label>
    <arm_group_label>Treatment 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stable CAD (coronary artery disease) defined by:

               -  clinically stable for at least 3 months

               -  coronary artery stenosis in any of the 3 main coronary vessels

               -  or history of myocardial infarction

          -  Sinus rhythm at screening

          -  Interpretable echocardiographic images

          -  Age: 30 to 80 years

          -  Body mass index (BMI): above/equal 18.0 and below/equal 36.0 kg/m²

        Exclusion Criteria:

          -  Ejection fraction (EF) below 30% at screening

          -  Progressive angina with symptoms of worsening of angina within the &lt;3 month

          -  History of recent myocardial infarction or unstable Angina

          -  Documented current relevant coronary stenosis ≥90% in any of the main 3 coronary
             vessels without bypass graft

          -  Symptomatic carotid stenosis, or transient ischemic attack or stroke within 3 months
             or patients with stroke at more than 3 months

          -  Insulin dependent diabetes mellitus

          -  Clinically significant and persisting cardiac ischemia

          -  Atrial fibrillation, pacemaker, defibrillator, second and third degree
             atrial-ventricular (AV) block

          -  Known clinically relevant ventricular arrhythmias

          -  Clinically relevant heart failure with reduced left ventricular ejection fraction

          -  Significant valvular heart disease with moderate or severe aortic stenosis or any
             other significant stenosis; any other moderate or severe valvular failures

          -  Valve replacement

          -  Hypertrophic obstructive cardiomyopathy (HOCM)

          -  Previous or imminent cardiac transplantation

          -  Known long QT syndrome or prolongation of the QT interval with ongoing proarrhythmic
             conditions

          -  Co-medication with drugs known to have QT prolonging effect

          -  Intolerance of fluoroquinolones, including moxifloxacin

          -  History of serious adverse effects e.g. tendinitis and tendon rupture, arthralgia and
             effects on the peripheral and central nervous system while taking fluoroquinolones
             including moxifloxacin

          -  History of tendon diseases or tendon injury caused by quinolones

          -  Treatment with fluoroquinolones, including moxifloxacin during the last 2 weeks

          -  Treatment with organic nitrates during the last 3 months

          -  Treatment with riociguat during the last 3 months

          -  Treatment with phosphodiesterase (PDE)-5 inhibitors during the last 14 days

          -  Systolic blood pressure below 110 or above 160 mmHg at screening visit

          -  Diastolic blood pressure below 50 or above 100 mmHg at screening visit

          -  Heart rate below 50 or above 100 beats/min (taken from ECG measurement) at first
             screening visit

          -  Estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m*2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitätsherzzentrum Freiburg - Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <state>Baden-Württemberg</state>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Einrichtungen der Universität Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SocraTec R&amp;D Clinical Ward</name>
      <address>
        <city>Erfurt</city>
        <state>Thüringen</state>
        <zip>99084</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum (CVK)</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAREXEL GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMSP Republican Clinical Hospital</name>
      <address>
        <city>Chisinau</city>
        <zip>MD2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <zip>2333 CL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Moldova, Republic of</country>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vericiguat</keyword>
  <keyword>Stable CAD</keyword>
  <keyword>QT/QTc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

